News

The patents for the company’s Skinfusion technology cover the intermediate formulation during manufacturing and the finished product for a transdermal patch containing estrogen and progestin used in contraception.

Bristol-Myers Squibb collaborates with ImClone on Erbitux in North America and is making the product commercially available through its wholly-owned subsidiary Bristol-Myers Squibb Canada. Erbitux is approved by

According to the company, Claro, the first hand-held device to use intense pulsed light for treatment of acne, will be available by prescription January 2009 from medical professionals,

The Phase I/IIa inter-patient dose escalation study will assess the safety and tolerability of repeated administration of Cytheris’s investigative immunotherapy, recombinant human Interleukin-7 (CYT107), as an add-on therapy

Additionally, as part of the merger, Clinical Data will issue contingent value rights to Avalon stockholders, payable for up to $2.5 million of additional shares of Clinical Data’s

Patented through 2018, Centany represents an important step in Medimetriks’ plan to commercialize patent-protected therapies for the dermatology and podiatry markets that offer important patient benefits. Medimetriks plans

The new patent covers several new chemical entities, including composition of matter and use of the company’s lead product candidate, OT-551. With anticipated patent life extensions, the patent

The product is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta blockers. Hi-Tech plans

The Phase IIb trial is being conducted at the Friedrich Alexander University Hospital in Erlangen, Germany, led by Eckhart Kampgen, associate professor for strategies of cellular immunotherapy at